Laurie Stephen of Ampersand Biosciences co-authored a protocol titled, “Multiplex Immunoassay Profiling of Hormones Involved in Metabolic Regulation.” This article features multiplex immunassays used for rapid profiling of biomarker proteins and small molecules in biological fluids.
Laurie Stephen of Ampersand Biosciences co-authored an article titled, “Necroptotic debris including damaged mitochondria elicits sepsis-like syndrome during late-phase tularemia.”
Species: Mouse, Non-Human Primates, Humans
Focus: Francisella Tularensis Ssp. Tularensis (Ft), SchuS4, Tularemia
Ampersand Biosciences was cited in the article titled, “Global analysis of gene expression reveals mRNA superinduction is required for the inducible immune response to a bacterial pathogen” for the use of sample testing services performed by Ampersand Biosciences using the Roden Map 4.0 cytokine bead array to measure cytokine and protein levels.
Species: Mouse
Focus: Immune Response, Gene Expression, Ummostimulatory Ligands, Lipopolysaccharide
Laurie Stephen of Ampersand Biosciences co-authored a chapter in Proteomic Methods in Neuropsychiatric Research titled, “Multiplex Immunoassay Profiling of Serum in Psychiatric Disorders.” This chapter features multiplex immunoassays that allow for rapid profiling of biomarker proteins in biological fluids, using less sample and labor than in single immunoassays.
Ampersand Biosicences was cited in the article titled, “Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells” for sample testing analysis performed by Ampersand Biosciences using 42 biomarkers on the Rodent Map v.4.0 platform.
Species: Mouse
Focus: Extracellular Vesicles (EVs)
Laurie Stephen of Ampersand Biosciences co-authored an article in the AAPS Journal titled, “Recommendations for Use and Fit-for-Purpose Validation of Biomarker Multiplex Ligand Binding Assays in Drug Development.” This article features multiplex assays and their complexity, how they create many unique challenges, and the purpose of biomarker multiplex ligand binding assays in drug development.